NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

Size: px
Start display at page:

Download "NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S."

Transcription

1 Final Belgian list: (Last update 13/03/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE LIMITED New Biological ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD, Cond Auth, ADEMPAS RIOCIGUAT BAYER PHARMA ALDURAZYME LARONIDASE GENZYME EUROPE B.V. Auth under excep circumstances, AMYVID FORBETAPIR (F-18) Q.S. ELI LILLY NEDERLAND BV ANORO GLAXO GROUP LTD UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE, APLEEK ETHINYL ESTRADIOL/GESTODENE BAYER PHARMA AG ARZERRA OFATUMUMAB MG/ML GLAXO GROUP LTD Conditional auth, ATRIANCE NELARABINE 5.00 MG/ML GLAXO GROUP LTD Auth under excep circumstances ATRYN ANTITHROMBIN ALFA GTC BIOTHERAPEUTICS UK LIMITED Auth under excep circumstances, AUBAGIO TERIFLUNOMIDE SANOFI-AVENTIS GROUPE BELLINA CHLORMADINONE, ETHINYLESTRADIOL GEDEON RICHTER Plc Outcome Referral Art 31, BEMFOLA Follitropin alfa FINOX Biotech AG New biological BENLYSTA BELIMUMAB GLAXO GROUP LTD BETMIGA MIRABEGRON ASTELLAS PHARMA EUROPE B.V. BEXSERO NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. NOVARTIS VACCINES & DIAGNOSTICS S.R.L. BINDREN COLESTILAN NOVARTIS VACCINES & DIAGNOSTICS S.R.L. BOSULIF BOSUTINIB (MONOHYDRATE) MG PFIZER LIMITED, Cond Auth, BRETARIS GENUAIR ACLIDINIUM BROMIDE ALMIRALL S.A, BRIMICA GENUAIR ACLIDINIUM BROMIDE/ FORMOTERL FUMARATE DIHYDRATE ALMIRALL S.A, BRINTELLIX VORTIOXETINE H. LUNDBECK A/S CAPRELSA VANDETANIB ASTRAZENECA AB, Cond Auth CEPLENE HISTAMINE DIHYDROCHLORIDE MEDA AB Auth under excep circumstances CERDELGA ELIGLUSTAT GENZYME EUROPE B.V., CHAMPIX VARENICLINE (TARTRATE) PFIZER LIMITED CINRYZE C1-INHIBITOR IU VIROPHARMA BVBA CLAUDIA - 35 ETHINYLESTRADIOL MCG, CYPROTERONE ACETATE 2.00 MG SANDOZ N.V. CLEVIPREX CLEVIDIPINE BUTYRATE THE MEDICINES COMPANY UK LTD COMETRIQ CABOZANTINIB TMC Pharma Services Ltd, Cond Auth CONSTELLA LINACLOTIDE ALMIRALL S.A CONVULEX VALPROIC ACID TAKEDA BELGIUM CORLENTOR IVABRADINE SERVIER, LES LABORATOIRES

2 COSENTYX SECUKINUMAB NOVARTIS EUROPHARM LIMITED CUPRYMINA COPPER (64-CU) CHLORIDE Q.S. SPARKLE S.R.L CYRAMZA RAMUCIRUMAB ELI LILLY NEDERLAND BV DACOGEN DECITABINE JANSSEN-CILAG INTERNATIONAL NV DAKLINZA DACLATASVIR BRISTOL MYERS SQUIBB/PFIZER EEIG DALIRESP ROFLUMILAST MCG NYCOMED GMBH DAPHNE ETHINYLESTRADIOL MCG, CYPROTERONE ACETATE 2.00 MG MITHRA PHARMACEUTICALS S.A. DAXAS ROFLUMILAST NYCOMED GMBH DEFITELIO DEFIBROTIDE Gentium New biological, authorised under exceptional circumstances DELTYBA DELAMANID Otsuka Novel Products GmbH, Cond Auth DEPAKINE SODIUM VALPROATE SANOFI BELGIUM DEPAKINE CHRONO SODIUM VALPROATE, VALPROIC ACID SANOFI BELGIUM DEPAKINE CHRONO SODIUM VALPROATE, VALPROIC ACID PI-PHARMA NV DEPAKINE ENTERIC SODIUM VALPROATE SANOFI BELGIUM DEPAKINE IV SODIUM VALPROATE SANOFI BELGIUM DIANE-35 ETHINYLESTRADIOL MCG, CYPROTERONE ACETATE 2.00 MG BAYER N.V. DIFICLIR FIDAXOMICIN ASTELLAS PHARMA EUROPE B.V. DOMPERIDON MYLAN DOMPERIDONE MALEATE MYLAN SPRL DOMPERIDON TEVA DOMPERIDONE MALEATE TEVA PHARMA BELGIUM N.V. DOMPERIDONE EG DOMPERIDONE MALEATE EUROGENERICS N.V. DOMPERIDONE INSTANT DOMPERIDONE EG EUROGENERICS N.V. DOMPERIDONE MYLAN DOMPERIDONE MALEATE MYLAN BVBA/SPRL DOMPERITOP DOMPERIDONE MALEATE APOTEX NV DUAKLIR GENUAIR ACLIDINIUM BROMIDE/ FORMOTERL FUMARATE DIHYDRATE ALMIRALL S.A EDARBI AZILSARTAN MEDOXOMIL (POTASSIUM) TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD EDURANT RILPIVIRINE (HYDROCHLORIDE) JANSSEN-CILAG INTERNATIONAL NV EKISTOL CILOSTAZOL??? Outcome Referral Art 31, EKLIRA GENUAIR ACLIDINIUM (BROMURE) ALMIRALL S.A., ELAPRASE IDURSULFASE SHIRE HUMAN GENETIC THERAPIES AB Auth under excep circumstances ELIQUIS APIXABAN BRISTOL MYERS SQUIBB/PFIZER EEIG ELISAMYLAN 35 ETHINYLESTRADIOL MCG, CYPROTERONE ACETATE 2.00 MG MYLAN BVBA/SPRL ELVANSE / TYVENSE LISDEXAMPHETAMINE BRYSTOL MYERS SQUIBB/ PFIZER EEIG ENTYVIO VEDOLIZUMAB TAKEDA PHARMA A/S

3 ENUREV BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, EPERZAN ALBIGLUTIDE GlaxoSmithKline Trading Services Limited ERIVEDGE VISMODEGIB ROCHE REGISTRATION LIMITED, Cond Auth ESBRIET PIRFENIDONE INTERMUNE EUROPE LTD, EURARTESIM PIPERAQUINE TETRAPHOSPHATE (TETRAHYDRATE), DIHYDROARTEMISININ (DHA) SIGMA-TAU INDUSTRIE FARMAC. RIUNITE SPA, EVARREST FIBRINOGEN, HUMAN Q.S., THROMBIN, HUMAN Q.S. OMRIX BIOPHARMACEUTICALS N.V. New Biological EVIPLERA ENOFOVIR DISOPROXIL (FUMARATE), EMTRICITABINE GILEAD SCIENCES LTD, RILPIVIRINE (HYDROCHLORIDE) EVOLTRA CLOFARABINE GENZYME EUROPE B.V. Auth under excep circumstances EXJADE DEFERASIROX NOVARTIS EUROPHARM LIMITED EXVIERA DASABUVIR ABBVIE LTD EYLEA AFLIBERCEPT BAYER AG EZICLEN SULPHATE ANHYDROUS, MAGNESIUM SULFATE HEPTAHYDRATE, POTASSIUM SULPHATE IPSEN PHARMA FAMPYRA FAMPRIDINE BIOGEN IDEC LTD, Cond Auth FIRDAPSE AMIFAMPRIDINE (PHOSPHATE) BIOMARIN EUROPE LTD Auth under excep circumstances, FLUENZ INFLUENZA VIRUS, LIVE, ATTENUATED Q.S. MEDIMMUNE LLC FLUENZ TETRA INFLUENZA VIRUS (LIVE, ATTENUATED Q.S., NASAL) MEDIMMUNE LLC FORXIGA DAPAGLIFLOZIN (PROPANEDIOL MONOHYDRATE) BRISTOL MYERS SQUIBB/ASTRAZENECA EEIG FYCOMPA PERAMPANEL EISAI EUROPE LTD GAZYVARO OBINUTUZUMAB ROCHE REGISTRATION LIMITED GEONISTIN OXYTETRACYCLIN, NYSTATIN Pliva Hrvatska d.o.o. GILENYA FINGOLIMOD (HYDROCHLORIDE) 0.50 MG NOVARTIS EUROPHARM LIMITED, GIOTRIF AFATINIB Boehringer Ingelheim International GLIVEC IMATINIB NOVARTIS EUROPHARM LIMITED GLYBERA ALIPOGENE TIPARVOVEC Q.S. UNIQURE BIOPHARMA B.V, Auth under excep circumstances, GRASTOFIL FILGASTRIM Apotex Europe New Biological GRATIELLA 35 ETHINYLESTRADIOL MCG, CYPROTERONE ACETATE 2.00 MG 3DDD PHARMA N.V. HAES-STERIL 6% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, HAES-STERIL 10% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, HALAVEN ERIBULIN (MESYLATE) 0.44 MG/ML EISAI LIMITED HARVONI LEDIPASVIR, SOFOSBUVIR GILEAD SCIENCES LTD HELEN CHLORMADINONE, ETHINYLESTRADIOL Mithra Pharmaceuticals S.A. Outcome Referral Art 31,

4 HEXACIMA HEXYON Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) SANOFI PASTEUR SA SANOFI PASTEUR MSD New Biological New Biological HIZENTRA IMMUNOGLOBULIN HUMAN NORMAL MG/ML BIOCLS GMBH New Biological HOLOCLAR EX VIVO EXPENDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS CHIESI FARMACEUTICI SPA, Cond Auth HYQVIA IMMUNOGLOBULIN HUMAN NORMAL MG/ML BAXTER INNOVATIONS GMBH New Biological ICLUSIG PONATINIB (HYDROCHLORIDE) ARIAD PHARMA LTD ILARIS CANAKINUMAB NOVARTIS EUROPHARM LIMITED Auth under excep circumstances, IMBRUVICA IBRUTINIB JANSSEN-CILAG INTERNATIONAL NV IMNOVID (POMALIDOMIDE POMALIDOMIDE CELGENE EUROPE LIMITED, CELGENE) IMVANEX Modified Vaccinia Ankara virus - Bavarian Nordic, Auth under excep BAVARIAN NORDIC A/S (MVA-BN) live virus circumstances INCIVO TELAPREVIR JANSSEN-CILAG INTERNATIONAL NV INCRELEX MECASERMIN IPSEN PHARMA Auth under excep circumstances, INCRESYNC ALOGLIPTIN/PIOGLITAZONE TAKEDA PHARMA A/S INCRUSE UMECLIDINIUM BROMIDE Glaxo Group Ltd INFLECTRA NFLIXIMAB HOSPIRA UK LTD New Biological INFLUSPLIT/ FLUARIX TETRA Influenza virus inactivated split virion GLAXO GROUP LTD Biological INLYTA AXITINIB PFIZER LIMITED INVOKANA CANAGLIFLOZIN JANSSEN-CILAG INTERNATIONAL NV IPREZIV AZILSARTAN MEDOXOMIL (POTASSIUM) TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD JAKAVI RUXOLITINIB (PHOSPHATE) NOVARTIS EUROPHARM LIMITED, JARDIANCE EMPAGLIFLOZIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH JAYDESS LEVONORGESTREL MG BAYER N.V. JENTADUETO METFORMIN HYDROCHLORIDE, LINAGLIPTIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH

5 JETREA OCRIPLASMIN THROMBOGENICS NV JEVTANA CABAZITAXEL SANOFI-AVENTIS GROUPE KADCYLA TRASTUZUMAB EMTANSINE ROCHE REGISTRATION LIMITED KALYDECO IVACAFTOR VERTEX PHARMACEUTICALS LIMIT, KETOCONAZOLE HRA KETOCONAZOLE LABORATOIRE HRA PHARMA KOLBAM (previously CHOLIC ACID FGK) CHOLIC ACID FGK Representative Service GmbH Auth under excep circumstances KRYSTEXXA PEGLOTICASE SAVIENT PHARMA IRELAND LIMITED, LACTEST GASILOXE Lactest S.L. / Venter Pharma S.L. LATUDA LURASIDONE TAKEDA PHARMA A/S LAVENTAIR UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE GLAXO GROUP LTD, LEMTRADA ALEMTUZUMAB GENZYME THERAPEUTICS LTD New Biological LIBERTEK ROFLUMILAST NYCOMED GMBH LOJUXTA LOMITAPIDE (MESYLATE) AEGERION PHARMACEUTICALS, Auth under excep circumstances LONQUEX LIPEGFILGRASTIM TEVA PHARMA BV, LYMPHOSEEK TILMANOCEPT NAVIDEA BIOPHARMACEUTICALS LIMITED LTD LYNPARZA OLAPARIB ASTRAZENECA AB LYXUMIA LIXISENATIDE SANOFI-AVENTIS GROUPE MACI CHONDROCYTES, AUTOLOGOUS CULTURED Q.S. GENZYME EUROPE B.V. MEKINIST TRAMETINIB GLAXO GROUP LTD MERIOFERT MENOTROPHIN LABORATOIRE GENEVRIER SA New Biological MOTILIUM DOMPERIDONE MALEATE JOHNSON & JOHNSON CONSUMER N.V. MOTILIUM DOMPERIDONE JOHNSON & JOHNSON CONSUMER N.V. MOTILIUM DOMPERIDONE PI-PHARMA NV MOTILIUM DOMPERIDONE IMPEXECO SA MOVENTIG NALOXEGOL ASTRAZENECA AG NAGLAZYME GALSULFASE BIOMARIN EUROPE LTD Auth under excep circumstances, NEURACEQ FLORBETABEN (18F) Piramal Imaging GmbH NEXOBRID PROTEOLYTIC ENZYMES (CONCENTRATE) ENRICHED IN MEDIWOUND GERMANY BROMELAIN, NIMENRIX NEISSERIA MENINGITIDES A+C+W+Y, POLYSACCHARIDE CONJ. TO TETANUS TOXOID Q.S. GLAXOSMITHKLINE BIOLOGICALS S.A., NOVOEIGHT Turoctocog alfa NOVO NORDISK A/S NOVOTHIRTEEN CATRIDECACOG NOVO NORDISK A/S NULOJIX BELATACEPT BRISTOL-MYERS SQUIBB PHARMA EEIG

6 NUMETZAH G16%E alanine, arginine, aspartic acid, calcium chloride, cysteine, glucose monohydrate, glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, magnesium acetate, methionine, olive oil, ornithine hydrochloride, henylalanine, potassium acetate, BAXTER S.A. Outcome Referral Art 31, proline, serine, sodium chloride, sodium glycerophosphate, soybean oil, taurine, threonine, tryptophan, tyrosine, valine NUWIQ SIMOCTOCOG ALFA OCTAPHARMA AB OFEV NINTEDANIB BOEHRINGER INGELHEIM INTERNATIONAL GMBH OLYSIO SIMEPREVIR JANSSEN-CILAG INTERNATIONAL NV OPGENRA EPTOTERMIN ALFA OLYMPUS BIOTECH LTD OPSUMIT MACITENTAN Actelion Registration Ltd OPTIMARK GADOVERSETAMIDE MALLINCKRODT MEDICAL GMBH OROPERIDYS DOMPERIDONE PIERRE FABRE MEDICAMENT ORPHACOL CHOLIC ACID LABORATOIRES CTRS Auth under excep circumstances OSSEOR STRONTIUM RANELATE SERVIER, LES LABORATOIRES OTEZLA APREMILAST CELGENE EUROPE LIMITED OVALEAP FOLLITROPIN ALPHA TEVA PHARMA GMBH New Biological PANDEMRIX INFLUENZA VIRUS (INACTIVATED) Q.S. GLAXOSMITHKLINE BIOLOGICALS S.A. PERJETA PERTUZUMAB ROCHE REGISTRATION LIMITED PICATO INGENOL MEBUTATE LEO PHARMA A/S PIXUVRI PIXANTRONE (DIMALEATE) CTI LIFE SCIENCES LTD, Cond Auth PLASMAVOLUME REDIBAG 6% HYDROXYETHYL STARCH BAXTER S.A. Outcome Referral Art 31, PLEGRIDY PEGINTERFERON BETA-1A BIOGEN IDEC LTD PLETAL CILOSTAZOL??? Outcome Referral Art 31, PROCORALAN IVABRADINE SERVIER, LES LABORATOIRES PROTELOS STRONTIUM RANELATE SERVIER, LES LABORATOIRES PROVENGE AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELLS ACTIVATED WITH PAP-GM-CS Q.S. DENDREON UK LIMITED, RELVAR ELLIPTA FLUTICASONE FUROATE: VILANTEROL TRIFENATATE GLAXO GROUP LTD, REMSIMA INFLIXIMAB CELLTRION HEALTHCARE HUNGARY KFT. New Biological REPLAGAL AGALSIDASE ALFA SHIRE HUMAN GENETIC THERAPIES AB Auth under excep circumstances, REVESTIVE TEDUGLUTIDE NYCOMED DANMARK APS,

7 REVLIMID LENALIDOMIDE CELGENE EUROPE LIMITED REVINTY ELLIPTA FLUTICASONE FUROATE: VILANTEROL TRIFENATATE GLAXO GROUP LTD RIENSO FERUMOXYTOL TAKEDA PHARMA A/S RIXUBIS NONACOG GAMMA BAXTER INNOVATIONS GMBH New Biological RYZODEG INSULIN ASPART UML, INSULIN DEGLUDEC UML NOVO NORDISK A/S SCENESSE AFAMELANOTIDE CLINUVEL UK LIMITED, Auth under excep circumstances SEEBRI BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, SELINCRO NALMEFENE (HYDROCHLORIDE DIHYDRATE) LUNDBECK A/S SENCHIO OSPEMIFENE SHIONOGI LIMITED New as, SIGNIFOR PASIREOTIDE (DIASPARTATE) NOVARTIS EUROPHARM LIMITED SIRTURO BEDAQUILINE JANSSEN-CILAG INTERNATIONAL NV, conditional auth SOMATROPIN BIOPARTNERS SOMATROPIN BIOPARTNERS New Biological SOVALDI SOFOSBUVIR GILEAD SCIENCES INTERNATIONAL LTD SPEDRA AVANAFIL VIVUS BV STIVARGA REGORAFENIB BAYER AG STRIBILD TENOFOVIR DISOPROXIL (FUMARATE), EMTRICITABINE, ELVITEGRAVIR, COBICISTAT GILEAD SCIENCES LTD STRIVERDI RESPIMAT OLODATEROL BOEHRINGER INGELHEIM INTERNATIONAL GMBH, SYLVANT SILTUXIMAB JANSSEN-CILAG INTERNATIONAL NV TAFINLAR DABRAFENIB GLAXOSMITHKLINE TRADING SERVICES LIMITED TARGOCID ACIPIMOX PFIZER TETRASPAN 6% HYDROXYETHYL STARCH B. BRAUN MELSUNGEN AG Outcome Referral Art 31, TETRASPAN 10% HYDROXYETHYL STARCH B. BRAUN MELSUNGEN AG Outcome Referral Art 31, TEYSUNO TEGAFUR, GIMERACIL, OTERACIL (MONOPOTASSIUM) NORDIC GROUP BV, TIVICAY DOLUTEGRAVIR ViiV Healthcare UK Limited TOVANOR BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, TRAJENTA LINAGLIPTIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH TRANSLARNA ATALUREN PTC Therapeutics Limited, conditional auth TRESIBA INSULIN DEGLUDEC NOVO NORDISK A/S TRIUMEQ DOLUTEGRAVIR, ABACAVIR, LAMIVUDINE VIIV HEALTHCARE UK Ltd TROBALT RETIGABINE GLAXO GROUP LTD TYBOST COBICISTAT Gilead Sciences

8 TYGACIL TIGECYCLINE PFIZER LIMITED TYSABRI NATALIZUMAB BIOGEN IDEC LTD TYVERB LAPATINIB (DITOSYLATE MONOHYDRATE) GLAXO GROUP LTD Conditional auth ULTIBRO BREEZHALER INDACATEROL (MALEATE), GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED ULUNAR BREEZHALER INDACATEROL (MALEATE), GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED VALPROATE MYLAN SODIUM VALPROATE MYLAN BVBA VALPROATE RETARD EG SODIUM VALPROATE, VALPROIC ACID EG VALPROATE RETARD MYLAN SODIUM VALPROATE MYLAN BVBA VALPROATE SANDOZ SODIUM VALPROATE, VALPROIC ACID SANDOZ NV VECTIBIX PANITUMUMAB MG/ML AMGEN EUROPE BV Conditional auth VEDROP TOCOPHEROL D-ALPHA (AS TOCOFERSOLAN) ORPHAN EUROPE SARL Auth under excep circumstances, VELPHORO Mixture of polynuclear iron(iii)-oxyhydroxide, sucrose Vifor Fresenius Medical Care Renal Pharma France and starches VENOHES 6% HYDROXYETHYL STARCH B. BRAUN MELSUNGEN AG Outcome Referral Art 31, VEPACEL INFLUENZA VIRUS (INACTIVATED) Q.S. BAXTER INNOVATIONS GMBH VIBATIV TELAVANCIN Clinigen Healthcare Limited VICTRELIS BOCEPREVIR MERCK SHARP & DOHME LTD VIEKIRAX OMBITASVIR, PARITAPREVIR, RITONAVIR ABBVIE LTD VIMIZIM ELOSULFASE ALFA BIOMARIN EUROPE LTD, VIPDOMET ALOGLYPTIN / METFORMIN TAKEDA PHARMA A/S VIPIDIA ALOGLYPTIN TAKEDA PHARMA A/S VITEKTA ELVITEGRAVIR Gilead Sciences International Ltd VIZAMYL FLUTEMETAMOL (18F) GE Healthcare Ltd VOKANAMET CANAGLIFLOZIN / METFORMIN HYDROCHLORIDE JANSSEN-CILAG INTERNATIONAL NV VOLULYTE 6% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, VOLUVEN 6% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, VOLUVEN 10% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, VONCENTO FACTOR VIII HUMAN IU, FACTOR VON WILLEBRAND IU TEVA PHARMA BV New Biological VOTUBIA EVEROLIMUS NOVARTIS EUROPHARM LIMITED Conditional auth VYNDAQEL TAFAMIDIS (MEGLUMINE) PFIZER LIMITED Auth under excep circumstances, New AS, XADAGO SAFINAMIDE ZAMBON SPA XAGRID XAGRID SHIRE PHARMACEUTICAL CONTRACTS LTD Auth under excep circumstances XALKORI CRIZOTINIB PFIZER LIMITED, Cond Auth XARELTO RIVAROXABAN MG BAYER SCHERING PHARMA AG

9 XGEVA DENOSUMAB AMGEN EUROPE BV New biological XIAPEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM AUXILIUM UK LIMITED XIGDUO DAPAGLIFLOZIN/METFORMIN BRISTOL MYERS SQUIBB/PFIZER EEIG XOFIGO Radium Ra 223 dichloride Bayer Pharma AG XOTERNA BREEZHALER INDACATEROL / GLYCOPYRRONIUM TEVA PHARMA BV XTANDI ENZALUTAMIDE ASTELLAS PHARMA EUROPE B.V. XULTOPHY INSULIN DEGLUDEC, LIRAGLUTIDE NOVO NORDISK A/S New Biological XYDALBA DALBAVANCIN DURATA THERAPEUTICS INTERNATIONAL bv YELLOX BROMFENAC (SODIUM SESQUIHYDRATE) CROMA-PHARMA GMBH YERVOY IPILIMUMAB BRISTOL-MYERS SQUIBB PHARMA EEIG, YONDELIS TRABECTEDIN PHARMA MAR SA Auth under excep circumstances ZALTRAP AFLIBERCEPT SANOFI-AVENTIS GROUPE ZELBORAF VEMURAFENIB ROCHE REGISTRATION LIMITED ZILIUM DOMPERIDONE MALEATE KELA PHARMA NV ZINFORO CEFTAROLINE FOSAMIL (ACETIC ACID SOLVATE MONOHYDRATE) ASTRAZENECA AB ZOELY THERAMEX S.r.l. NOMOGESTROL ACETATE / ESTRADIOL HEMIHYDRATE ZONTIVITY VORAPAXAR MERCK SHARP & DOHME LTD ZYDELIG IDELALISIB GILEAD SCIENCES INTERNATIONAL LTD ZYTIGA ABIRATERONE ACETATE JANSSEN-CILAG INTERNATIONAL NV NOTE In Red in Black in blue in grey New Biological commercialised / commercialisé / gecommercialiseerd not commercialised / pas commercialisé / niet gecommercialiseerd info not yet available / info non disponible / info niet beschikbaar New addition of this month / nouvelle addition de ce mois / nieuwe toevoeging van deze maand nouvelle substance active / nieuw actief bestanddeel nouveau médicament biologique / nieuwe biologische geneesmiddel Etude de sécurité post-autorisation / post-autorisatie veiligheidsstudies

10 Conditional auth Auth under excep circumstances Autorisé sous certaines conditions / vergund onder bepaalde voorwaarden autorisé sous circonstances exceptionnelles / vergund onder uitzonderlijke omstandigheden Product informations / informations sur les produits / produkten informaties informations sur les produits/productinformatie

AMYVID FORBETAPIR (F 18) Q.S. ELI LILLY NEDERLAND BV New AS ARZERRA OFATUMUMAB 20.00 MG/ML GLAXO GROUP LTD Conditional auth, PASS

AMYVID FORBETAPIR (F 18) Q.S. ELI LILLY NEDERLAND BV New AS ARZERRA OFATUMUMAB 20.00 MG/ML GLAXO GROUP LTD Conditional auth, PASS Final Belgian list: marketing name Active substance MAH Reason on list ADASUVE LOXAPINE ALEXZA UK LTD New AS ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD New AS, Cond Auth, PASS

More information

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. Final Belgian list: (Last update 02/12/2013) marketing name Active substance MAH Reason on list ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD, Cond Auth, ALDURAZYME LARONIDASE GENZYME

More information

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. Final Belgian list: (Last update 07/02/2014) marketing name Active substance MAH Reason on list ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD, Cond Auth, ALDURAZYME LARONIDASE GENZYME

More information

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. Final Belgian list: (Last update 07/10/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE

More information

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. Final Belgian list: (Last update 07/10/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE

More information

13 ADDITIONS - 1 RETRAIT

13 ADDITIONS - 1 RETRAIT Final Belgian list: (Last update 07/12/2015) marketing name Active substance MAH Reason on list Monthly modifications: +/- 13 ADDITIONS - 1 RETRAIT ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS

More information

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1 March 2015 Welcome to the first COMPARE report. This report provides information

More information

NEW DRUG APPROVALS IN ICH COUNTRIES 2004 2013 FOCUS ON 2013

NEW DRUG APPROVALS IN ICH COUNTRIES 2004 2013 FOCUS ON 2013 24 24 24 Approval time (days) Approval time (years) NEW DRUG APPROVALS IN ICH COUNTRIES 24 FOCUS ON Median 25 th and 75 th percentile 12 1 8 6 NASs approval time by approval year 24- Median; 25 th and

More information

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use 25 April 2014 EMA/237058/2014 Procedure Management and Business Support Division Applications for new human under evaluation by the Committee for Medicinal Products for Human Use April 2014 This document

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > June 2014 Specialty Pipeline Update New Drug Information Eloctate (recombinant factor VIII Fc fusion protein): Biogen received FDA approval for their hemophilia A for

More information

PATIENT ASSISTANCE PROGRAMS

PATIENT ASSISTANCE PROGRAMS PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed

More information

ATC/DDD Classification

ATC/DDD Classification ATC/DDD Classification ATC/DDD Classification (Temporary) The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology

More information

Manufacturer of drug substance

Manufacturer of drug substance Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin

More information

Biggest Launches 2014

Biggest Launches 2014 Biggest Launches 2014 The recent staggering performance of the biotech industry has been built around a belief that the sector s R&D productivity is on the rebound and will deliver huge investor returns

More information

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

Special Authorization

Special Authorization Special Authorization Certain medications in the Reformulary require Special Authorization from your insurance company before your prescription is eligible for coverage. What is Special Authorization?

More information

WORLD PREVIEW 2014, OUTLOOK TO 2020

WORLD PREVIEW 2014, OUTLOOK TO 2020 WORLD PREVIEW 2014, OUTLOOK TO 2020 June 2014 Welcome to the EvaluatePharma World Preview 2014, Outlook to 2020 The seventh edition of EvaluatePharma s World Preview brings together many of our analyses

More information

Lists of medicinal products for rare diseases in Europe*

Lists of medicinal products for rare diseases in Europe* October 2015 Lists of medicinal products for rare diseases in Europe* *European Community marketing authorisation under the centralised procedure www.orpha.net General Table of contents PART 1: List of

More information

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste The Newcastle upon Tyne Hospitals NHS Foundation Trust Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste Version.: 1.1 Effective From: 20 January 2016 Expiry Date: 20 January 2019 Date

More information

Drugs Not Approved By the Scottish Medicines Consortium

Drugs Not Approved By the Scottish Medicines Consortium December 2014 Vol. 11 No. 3 Outlined below in this newsletter are the recommendations for new drugs which have been through the locally agreed process (see appendix I). Please remember that the ADTC advises

More information

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for

More information

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG Monitoring Usage in Wales of s Appraised by NICE and AWMSG October 2014 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology

More information

Liste des médicaments pour les maladies rares en Europe*

Liste des médicaments pour les maladies rares en Europe* Janvier 2016 Liste des médicaments pour les maladies rares en Europe* *Autorisation de mise sur le marché de la Communauté Européenne par procédure centralisée www.orpha.net Sommaire général PARTIE 1:

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

EU Clinical Trials Register

EU Clinical Trials Register EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 [email protected]

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 9 July 2015 EMA/483660/2015 Procedure Management and Committees Support Active substance: diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated), haemophilus type b conjugate

More information

1 ST QUARTER 2015 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES

1 ST QUARTER 2015 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES February 2015 1 ST QUARTER 2015 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the 1 st Quarter 2015 update to the Highmark Drug Formularies and pharmaceutical management procedures. The

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room Guide The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use 23 June 206 EMA/40396/206 - corr Information Management Division Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use June 206 This document lists

More information

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012 The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered

More information

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Elenchi dei prodotti medicinali per le malattie rare in Europa*

Elenchi dei prodotti medicinali per le malattie rare in Europa* Luglio 2015 Elenchi dei prodotti medicinali per le malattie rare in Europa* *Autorizzazione all immissione in commercio della Comunità Europea nell ambito della procedura centralizzata www.orpha.net Indice

More information

Listados de medicamentos para enfermedades raras en Europa*

Listados de medicamentos para enfermedades raras en Europa* Octubre 2015 Listados de medicamentos para enfermedades raras en Europa* *Autorización de comercialización de la Comunidad Europea mediante el procedimiento centralizado www.orpha.net Índice general PARTE

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

Human Tubal Fluid (HTF) Media & Modifi ed Human Tubal Fluid (mhtf) Medium with Gentamicin

Human Tubal Fluid (HTF) Media & Modifi ed Human Tubal Fluid (mhtf) Medium with Gentamicin Human Tubal Fluid (HTF) Media & Modifi ed Human Tubal Fluid (mhtf) Medium with Gentamicin HTF Media are intended for use in assisted reproductive procedures which include gamete and embryo manipulation

More information

Pharma working capital leaves room for improvement

Pharma working capital leaves room for improvement October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.

More information

FDA Office of Hematology and Oncology Products (OHOP) 2011 Review

FDA Office of Hematology and Oncology Products (OHOP) 2011 Review FDA Office of Hematology and Oncology Products (OHOP) 2011 Review 1 OHOP 130 total employees 55 oncologists including 9 pediatric oncologists 25 PhDs in Pharmacology/Toxicology 24 Regulatory Project Managers

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

Verzeichnis der Arzneimittel für seltene Krankheiten in Europa*

Verzeichnis der Arzneimittel für seltene Krankheiten in Europa* Oktober 2014 Verzeichnis der Arzneimittel für seltene Krankheiten in Europa* *Zentrales Zulassungsverfahren der Europäischen Gemeinschaft www.orpha.net Allgemeiner Überblick des Inhaltes TEIL 1: Verzeichnis

More information

EvaluatePharma World Preview 2015, Outlook to 2020

EvaluatePharma World Preview 2015, Outlook to 2020 EvaluatePharma World Preview 2015, Outlook to 2020 8th Edition June 2015 Welcome to the EvaluatePharma World Preview 2015, Outlook to 2020 The eighth edition of EvaluatePharma s World Preview brings together

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Malignant Mesothelioma - Pipeline Review, H1 2015

Malignant Mesothelioma - Pipeline Review, H1 2015 Brochure More information from http://www.researchandmarkets.com/reports/3308784/ Malignant Mesothelioma - Pipeline Review, H1 2015 Description: Malignant Mesothelioma - Pipeline Review, H1 2015 Summary

More information

Listes des médicaments pour les maladies rares en Europe*

Listes des médicaments pour les maladies rares en Europe* Avril 2014 Listes des médicaments pour les maladies rares en Europe* *Autorisation de mise sur le marché de la Communauté Européenne par procédure centralisée www.orpha.net Sommaire général PARTIE 1: Liste

More information

Preferred Drug List Updates Effective: Jan. 1, 2016

Preferred Drug List Updates Effective: Jan. 1, 2016 Molina Healthcare regularly reviews and updates the Preferred Drug List (PDL). Items may be added, removed or changed. Below is the list of updates made to the PDL this quarter. Some items require a prior

More information

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 July 2014 Review of the List of High-Cost Medicines Used by the

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

The type 2 diabetes market is undergoing a paradigm

The type 2 diabetes market is undergoing a paradigm Elsevier Business Intelligence PRESCRIPTION PHARMACEUTICALS AND BIOTECHNOLOGY July 16, 2012 Founded 1939 In A Changing Diabetes Drug Market, Who Will Come Out On Top? Jessica Merrill [email protected]

More information

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:

More information

SMC Accepted Medicine Indication Formulary Decision To be used on Treatment of unresectable or metastatic, well- or everolimus (Afinitor) Novartis

SMC Accepted Medicine Indication Formulary Decision To be used on Treatment of unresectable or metastatic, well- or everolimus (Afinitor) Novartis SMC Accepted Medicine Indication Formulary Decision To be used on Treatment of unresectable or metastatic, well- or everolimus (Afinitor) Novartis advice moderately-differentiated neuroendocrine Pharmaceuticals

More information

Pharmaceutical Marketing Disclosures

Pharmaceutical Marketing Disclosures Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,

More information

Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease

Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease Cigna Specialty Pharmacy Services Limited Distribution and Risk Evaluation Mitigation (RE) Drug List Last updated on 04/06/2015 Medication Brand Name Condition Actemra Rheumatroid Arthritis Acthar Seizure

More information

Marketing authorisations granted in March 2016

Marketing authorisations granted in March 2016 PL 10321/0204 01/03/2016 RESOLUTION CHEMICALS LIMITED HYDROCORTISONE 10 MG TABLETS HYDROCORTISONE 10.00 MILLIGRAMMES POM PL 10321/0205 01/03/2016 RESOLUTION CHEMICALS LIMITED HYDROCORTISONE 20 MG TABLETS

More information

Orphan drugs program. Discussion paper. May 2015

Orphan drugs program. Discussion paper. May 2015 Orphan drugs program Discussion paper About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible

More information

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Insulin Use in Type 2 Diabetes A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes

More information

May 2013 Declining Medicine Use and Costs: For Better or Worse?

May 2013 Declining Medicine Use and Costs: For Better or Worse? May 2013 Declining Medicine Use and Costs: For Better or Worse? A Review of the Use of Medicines in the United States in 2012 Introduction In 2012, both the per capita use and cost of medicines declined.

More information

Great-West s Drug Prior Authorization

Great-West s Drug Prior Authorization Great-West s Drug Prior Authorization Great-West Life s prior authorization process is designed to provide an effective approach to managing claims for specific prescription drugs. Approval for coverage

More information

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Prostate Cancer: Key Metrics in the 9MM, 2013 2023 2013 Epidemiology

More information

Fourth Quarter 2014 Provider Connection

Fourth Quarter 2014 Provider Connection Healthy Michigan Plan Health Risk Assessments Do you need clarification or information related to the completion of the Healthy Michigan Plan (HMP) member Health Risk Assessment (HRA) form? Resources and

More information

Drug Formulary Update, July 2014 Commercial and State Programs

Drug Formulary Update, July 2014 Commercial and State Programs Drug ormulary Update, July 2014 Commercial and State Programs Updates to the HealthPartners Drug ormularies are listed below. Changes start July 1 unless noted otherwise. Updates apply to all Commercial

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

Indication: Posology: Indication: Posology:

Indication: Posology: Indication: Posology: Maklumat tambahan indikasi untuk upload pada laman web Year 2014 Products Approved For Additional Indication (DCA 275 9 Mei 2014) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 Trajenta Duo 2.5mg/500mg Film-Coated

More information

Global Pharmaceuticals Marketing Channel Reference EDITION

Global Pharmaceuticals Marketing Channel Reference EDITION Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry

More information

Robert Ancuceanu for his exceptional work as he has resigned from the Committee and adopted the following opinions:

Robert Ancuceanu for his exceptional work as he has resigned from the Committee and adopted the following opinions: News from the EMA Activities of the PDCO During its meeting from 10-12 November 2010 the Paediatric Committee (PDCO) thanked Robert Ancuceanu for his exceptional work as he has resigned from the Committee

More information

supplement 18 PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE 4ML CONCENTRATE FOR SOLUTION FOR INFUSION x 1VIAL

supplement 18 PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE 4ML CONCENTRATE FOR SOLUTION FOR INFUSION x 1VIAL supplement 18 NOM DOSAGE FORME NR ST LABORATOIRE PAYS D'ORIGINE ACTEMRA 80MG/4ML 4ML CONCENTRATE FOR SOLUTION FOR INFUSION x 218156/09 * CHUGAI PHARMA MANUFACTURING CO LTD FOR F.HOFFMANN-LA ROCHE LTD -

More information

meeting report on the review of applications for orphan designation

meeting report on the review of applications for orphan designation 13 June 2014 EMA/COMP/309595/2014 Committee for Orphan Medicinal Products (COMP) Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation June

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS Adopted November 2013, in force since 1 st of January 2014. INTRODUCTION The Association

More information

Juli 2016 Verzeichnis der Arzneimittel für seltene Krankheiten in Europa*

Juli 2016 Verzeichnis der Arzneimittel für seltene Krankheiten in Europa* Juli 2016 Verzeichnis der Arzneimittel für seltene Krankheiten in Europa* *Zentrales Zulassungsverfahren der Europäischen Gemeinschaft www.orpha.net www.orphadata.org Allgemeiner Überblick des Inhaltes

More information

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product

More information

Global Peptide Therapeutics Market 2014-2018

Global Peptide Therapeutics Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences

More information

PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE A-CNOTREN 20MG 30 SOFT CAPSULES 218180/09 * GAP S.A FOR PHARMATHEN S.A GRECE ACUVAIL 0.

PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE A-CNOTREN 20MG 30 SOFT CAPSULES 218180/09 * GAP S.A FOR PHARMATHEN S.A GRECE ACUVAIL 0. NOM DOSAGE FORME NR ST LABORATOIRE PAYS D'ORIGINE A-CNOTREN 20MG 30 SOFT CAPSULES 218180/09 * GAP S.A FOR PHARMATHEN S.A GRECE ACUVAIL 0.45% 0.4ML X 30 SINGLE USE VIALS 097674/11 ALLERGAN SALES LLC USA

More information

Novel OAC s : How should we use them?

Novel OAC s : How should we use them? Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker

More information

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

SPECIAL AUTHORIZATION GUIDELINES

SPECIAL AUTHORIZATION GUIDELINES 91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage

More information

GSK Product development pipeline

GSK Product development pipeline GSK Product development pipeline March 2015 Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party *

More information

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications

More information

Multiple Sclerosis Drug Discoveries - What the Future Holds

Multiple Sclerosis Drug Discoveries - What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

More information

Listes des médicaments pour les maladies rares en Europe*

Listes des médicaments pour les maladies rares en Europe* Janvier 2014 Listes des médicaments pour les maladies rares en Europe* *Autorisation de mise sur le marché de la Communauté Européenne par procédure centralisée www.orpha.net Sommaire général PARTIE 1:

More information

Biopharmaceutical Raw Materials throughout the Product Lifecycle

Biopharmaceutical Raw Materials throughout the Product Lifecycle February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing

More information

New Drug Approvals. Elizabeth A. Shlom, PharmD, BCPS President, NYSCHP SVP/Director, Clinical Pharmacy Services GNYHA Services, Inc.

New Drug Approvals. Elizabeth A. Shlom, PharmD, BCPS President, NYSCHP SVP/Director, Clinical Pharmacy Services GNYHA Services, Inc. New Drug Approvals 2014 Elizabeth A. Shlom, PharmD, BCPS President, NYSCHP SVP/Director, Clinical Pharmacy Services GNYHA Services, Inc. New York, NY Program Objectives By the end of the presentation,

More information

DRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION

DRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION ACTEMRA (toclizumab) 10/21/13 ADASUVE (loxapine aerosol powder breath activated) 01/24/14 ADDAMEL N INJ (Trace Min (CR-CU-F-FE-I-MN-MO-SE-ZN) INJ) 05/20/13 ADYNOVATE (Antihemophilic Factor Recomb Pegylated

More information

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician

More information